Our Mission

RxBio’s mission is to discover and develop novel and proprietary medications for the benefit of humankind.

Our Technology Platform

Acute Radiation Syndrome (ARS)
Secretory Diarrhea
NSAID-Induced
Gastric Erosions


News & Milestones

CEO Money

RxBio CEO Dr. W. Shannon McCool is Featured on the "CEO Money" (Segments 2 & 3) Program Airing August 22, 2017, on World Finance News 1.

SBIR (NIH) Funds RxBio Work

SBIR (NIH) Funds RxBio Work Assessing the Anti-Diarrheal Potential of an LPA analog Rx100.

See all News & Milestones

About us

RxBio, Inc. is an early-stage pharmaceutical company. RxBio was formed around novel and proprietary, small-molecule technology developed at the University of Tennessee Health Science Center (UTHSC) in Memphis and licensed from the University of Tennessee Research Foundation (UTRF).

The company's primary focus is the discovery and development of novel and proprietary compounds for use in the mitigation of acute radiation syndrome (ARS) – including gastrointestinal acute radiation syndrome (GI-ARS) as well as hematological radiation syndrome (HEM-ARS).

GI-ARS occurs as a result of unintended exposure to lethal doses of ionizing radiation (i.e. nuclear-weapon detonation, during manufacture and development of nuclear energy materials, following nuclear accidents, etc.). Government estimates are that many thousands would likely be at risk of developing ARS following detonation of an improvised nuclear device. Treating GI-ARS is the current limiting step in survival. There is no current therapy for this devastating and life-threatening condition. Read More